← Leaderboards
Martin Carroll
Philadelphia Va Medical Center
$11,311,520
Attributed
$11,311,520
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,313,431 · 11
VA$0 · 2
By mechanism
R01$7,561,130 · 3
U54$3,883,342 · 3
R21$1,433,118 · 3
P30$1,260,017 · 1
K08$175,824 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingMalignant NeoplasmsXenograft ProcedureLeadCellsIn VivoChemotherapyRelapseLaboratoriesResponseMutationMolecularBaseNovel TherapeuticsSignal TransductionPennsylvaniaIn VitroLeukemiaProteinsCohortMalignant - DescriptorComplexEpigenetic ProcessLeukemic Cell
Grant awards (46)
University of Pennsylvania Patient-derived Xenograft Development and Trials Center$1,062,215
U54 · FY2025 · CA · contact PI
Acute myeloid leukemia (AML) Research Project$230,344
U54 · FY2025 · CA · contact PI
University of Pennsylvania Patient-derived Xenograft Development and Trials Center$68,446
U54 · FY2025 · CA · contact PI
University of Pennsylvania Patient-derived Xenograft Development and Trials Center$1,009,106
U54 · FY2024 · CA · contact PI
Acute myeloid leukemia (AML) Research Project$218,826
U54 · FY2024 · CA · contact PI
University of Pennsylvania Patient-derived Xenograft Development and Trials Center$65,025
U54 · FY2024 · CA · contact PI
Pathologic Signaling Pathways in AML Cells$0
I01 · FY2024 · VA · contact PI
University of Pennsylvania Patient-derived Xenograft Development and Trials Center$930,590
U54 · FY2023 · CA · contact PI
Acute myeloid leukemia (AML) Research Project$230,344
U54 · FY2023 · CA · contact PI
University of Pennsylvania Patient-derived Xenograft Development and Trials Center$68,446
U54 · FY2023 · CA · contact PI
Pathologic Signaling Pathways in AML Cells$0
I01 · FY2023 · VA · contact PI
Pathologic Signaling Pathways in AML Cells$0
I01 · FY2022 · VA · contact PI
Pathologic Signaling Pathways in AML Cells$0
I01 · FY2021 · VA · contact PI
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia$643,241
R01 · FY2019 · CA · contact PI
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia$663,135
R01 · FY2018 · CA · contact PI
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia$663,135
R01 · FY2017 · CA · contact PI
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia$663,135
R01 · FY2016 · CA · contact PI
How Does FLT3 Mutation Regulate Myeloid Differentiation in Acute Myeloid Leukemia$208,880
R21 · FY2016 · CA · contact PI
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia$679,353
R01 · FY2015 · CA · contact PI
Stem Cells, Differentiation and Therapeutic Resistance in AML$591,204
R01 · FY2015 · CA · contact PI
How Does FLT3 Mutation Regulate Myeloid Differentiation in Acute Myeloid Leukemia$187,398
R21 · FY2015 · CA · contact PI
(PDQ5)Integrated Genetic and Epigenetic Prognostication for Acute Myeloid Leukemi$139,200
R21 · FY2015 · CA · contact PI
Core D: Xenotransplantation Mouse Core$80,810
P30 · FY2015 · DK · contact PI
Therapeutic targeting of Src kinase signal transduction pathways in AML$0
I01 · FY2015 · VA · contact PI
Stem Cells, Differentiation and Therapeutic Resistance in AML$575,611
R01 · FY2014 · CA · contact PI
(PDQ5)Integrated Genetic and Epigenetic Prognostication for Acute Myeloid Leukemi$243,600
R21 · FY2014 · CA · contact PI
Core D: Xenotransplantation Mouse Core$214,942
P30 · FY2014 · DK · contact PI
Therapeutic targeting of Src kinase signal transduction pathways in AML$0
I01 · FY2014 · VA · contact PI
Stem Cells, Differentiation and Therapeutic Resistance in AML$560,763
R01 · FY2013 · CA · contact PI
Core D: Xenotransplantation Mouse Core$238,940
P30 · FY2013 · DK · contact PI
Therapeutic targeting of Src kinase signal transduction pathways in AML$0
I01 · FY2013 · VA · contact PI
Stem Cells, Differentiation and Therapeutic Resistance in AML$599,584
R01 · FY2012 · CA · contact PI
Core D: Xenotransplantation Mouse Core$214,942
P30 · FY2012 · DK · contact PI
Therapeutic targeting of Src kinase signal transduction pathways in AML$0
I01 · FY2012 · VA · contact PI
Stem Cells, Differentiation and Therapeutic Resistance in AML$655,318
R01 · FY2011 · CA · contact PI
A Phase I/II Trial of Eltrombopag in Elderly Acute Myeloid Leukemia Patients$322,040
R21 · FY2011 · CA · contact PI
Core D: Xenotransplantation Mouse Core$224,393
P30 · FY2011 · DK · contact PI
A Phase I/II Trial of Eltrombopag in Elderly Acute Myeloid Leukemia Patients$332,000
R21 · FY2010 · CA · contact PI
Core D: Xenotransplantation Mouse Core$285,990
P30 · FY2010 · DK · contact PI
The Role of BCR/ABL in Regulating DNA Repair$246,470
R01 · FY2008 · CA · contact PI
The Role of BCR/ABL in Regulating DNA Repair$246,470
R01 · FY2007 · CA · contact PI
The Role of BCR/ABL in Regulating DNA Repair$253,831
R01 · FY2006 · CA · contact PI
The Role of BCR/ABL in Regulating DNA Repair$259,940
R01 · FY2005 · CA
The Role of BCR/ABL in Regulating DNA Repair$259,940
R01 · FY2004 · CA
MECHANISMS OF TRANSFORMATION BY TEL PDGFBR$87,912
K08 · FY2001 · CA
MECHANISMS OF TRANSFORMATION BY TEL PDGFBR$87,912
K08 · FY2000 · CA